Core Viewpoint - The implementation plan for the high-quality development of the traditional Chinese medicine (TCM) industry from 2026 to 2030 aims to establish a collaborative development system for the entire TCM industry chain by 2030 [1] Group 1: Quality Improvement - The plan emphasizes the importance of improving the quality of raw materials by establishing high-standard production bases in major production areas [2] - Factors such as origin, climate, soil, and cultivation techniques significantly affect the quality of medicinal materials, which in turn impacts the therapeutic effects of TCM [2] - As of June 2025, China has supported artificial breeding of 14 endangered medicinal materials and has achieved industrial production of substitutes for rare materials [2] Group 2: Innovation and Collaboration - The plan proposes collaborative innovation initiatives to enhance the transformation of TCM preparations in medical institutions, focusing on overcoming technological bottlenecks [3] - A cooperative model involving renowned doctors, hospitals, schools, and enterprises is encouraged to integrate resources effectively [3] - The Beijing Daxing District's Guang'anmen Hospital has successfully transformed over 20 TCM varieties, with 4 of them becoming innovative TCM drugs [3] Group 3: Digital Transformation - The plan outlines actions to enhance manufacturing capabilities, including the establishment of 20 smart factories and the cultivation of 10 green factories [4] - The application of smart devices in the TCM industry is expected to facilitate the transition from traditional experience-based practices to precision-based methods [4] - The use of artificial intelligence and big data is aimed at constructing knowledge graphs for classic formulas and experiences from renowned TCM practitioners [4] Group 4: Future Outlook - The next five years are deemed critical for the transformation and upgrading of the TCM industry, with expectations for further modernization and high-quality development as the plan's measures are implemented [5]

Core Viewpoint - The implementation plan for the high-quality development of the traditional Chinese medicine (TCM) industry has been jointly issued by eight departments, aiming to establish a collaborative development system for the entire TCM industry chain by 2030 [1]. Group 1: Quality Improvement of Raw Materials - The plan emphasizes the importance of improving the quality of raw materials, proposing the establishment of high-standard production bases for TCM raw materials in major production areas [2]. - Factors such as origin, climate, soil, and cultivation techniques significantly influence the quality of medicinal materials, which directly affects the therapeutic effects of TCM [2]. - As of June 2025, China has supported the artificial breeding of 14 endangered medicinal materials, with over 300 out of 600 commonly used TCM materials already achieving artificial cultivation [2]. Group 2: Innovation and Transformation - The plan calls for collaborative innovation to promote the transformation of TCM preparations in medical institutions, addressing technological bottlenecks through cooperation among renowned doctors, hospitals, schools, and enterprises [3]. - Modern production lines in TCM facilities are being utilized for the mass production of hospital preparations, indicating a shift towards industrialized TCM [3]. Group 3: Digital and Intelligent Transformation - The plan proposes actions to enhance manufacturing capabilities, including the establishment of 20 smart factories and the cultivation of 10 green factories, alongside the revision of 10 industry standards related to digital technology in TCM [4]. - The application of smart devices in the TCM industry is expected to facilitate the transition from traditional experience-based practices to precision-based methods [4]. - The integration of artificial intelligence and big data is set to create knowledge graphs for classic formulas and experiences from renowned TCM practitioners, enhancing research and resource distribution in the field [4]. Group 4: Future Outlook - The next five years are identified as a critical period for the transformation and upgrading of the TCM industry, with expectations for further modernization and high-quality development as the proposed measures are implemented [5].

Group 1 - The core viewpoint of the news is the introduction of 137 key investment projects in Yunnan Province for 2026, with a total planned investment of 111.5 billion yuan, covering 16 prefectures and cities [1] - The projects align with the "4+5+6" modern industrial system, focusing on resource-based industries, characteristic advantageous industries, and strategic emerging industries [1] - Resource-based industries include 17 projects with a planned investment of 16.1 billion yuan, while characteristic advantageous industries have 64 projects with a planned investment of 57.26 billion yuan, and strategic emerging industries consist of 56 projects with a planned investment of 38.15 billion yuan [1] Group 2 - In Kunming, there are 12 projects, including a 5G data park and a digital economy industrial park, with a focus on a shareholding cooperation model for the high-end pharmaceutical industry [2] - The investment opportunities list released by Yunnan Province outlines the region's comparative advantages in resources, location, industry, and openness, providing a clear guide for enterprises [3] - The comparative advantage list includes 28 key areas showcasing Yunnan's resource endowment and development potential, emphasizing its rich mineral resources and strategic location for cross-border logistics [3] Group 3 - The project list targeting private capital covers 343 projects across 11 key sectors, with a total investment of 223.12 billion yuan, balancing public welfare and commercial viability [4]

Core Viewpoint - The implementation plan for the high-quality development of traditional Chinese medicine (TCM) industry aims to establish a collaborative development system by 2030, enhancing the supply capacity of key TCM raw materials and promoting innovation in TCM products [1][2] Group 1: Development Goals - By 2030, the TCM industry is expected to form a collaborative development system across the entire industry chain, with a focus on enhancing the stable supply of key TCM raw materials and improving digital and green levels [1] - The plan includes the cultivation of 60 high-standard TCM raw material production bases and the establishment of five TCM industrial innovation centers [1] Group 2: Innovation and Market Trends - The plan emphasizes the need for continuous innovation in TCM products, aiming to approve a batch of innovative TCM drugs and cultivate 10 major varieties of traditional Chinese medicine [2] - Companies are encouraged to shift from "sales-driven" to "innovation-driven" strategies to enhance their core competitiveness in a market characterized by homogenization [2] Group 3: Research and Development Requirements - TCM companies are required to conduct high-level evidence-based medical research to provide clear efficacy and safety data, targeting unmet medical needs for precise treatment [2] - Establishing a comprehensive digital quality control system from raw materials to finished products is essential for ensuring product reliability [2] Group 4: Digital Transformation - The plan highlights the importance of "digital intelligence" in transforming the TCM industry from traditional practices to modern scientific management [4][5] - Emphasizing digital intelligence aims to standardize and optimize production processes, ensuring consistent product quality and meeting regulatory requirements [6] Group 5: Support for Industry Leaders - The plan proposes actions to cultivate outstanding enterprises in the TCM industry, supporting leading companies in establishing development funds and providing financial services [6] - It encourages the formation of innovation consortia to drive technological advancements and improve the overall modernization level of the TCM industry [6]

Core Viewpoint - The "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" aims to establish a collaborative development system for the entire industry chain by 2030, enhancing the stable supply of key raw materials, improving digital and green transformation levels, achieving breakthroughs in key technologies, and significantly increasing collaborative innovation levels [3][14]. Group 1: Development Goals - The plan sets four main goals: improving development quality, enhancing collaborative systems, fostering innovative products, and achieving breakthroughs in digital and green transformation [4][15]. - Specific tasks include cultivating 60 high-standard raw material production bases and establishing five innovation centers for the traditional Chinese medicine industry [4][15]. - The plan aims to promote the approval of innovative traditional Chinese medicine drugs and develop 10 major new traditional Chinese medicine products [4][15]. Group 2: Specific Actions - The plan outlines 15 specific tasks focusing on actions such as improving raw material quality and supply, collaborative innovation, enhancing manufacturing capabilities, revitalizing the national medicine industry, promoting traditional Chinese medicine products, and nurturing outstanding enterprises [5][16]. - It emphasizes the establishment of high-standard raw material production bases and the development of intelligent circulation and storage management systems for traditional Chinese medicine materials [7][18]. Group 3: Innovation and Technology - The plan encourages the use of artificial intelligence and big data to enhance the research and development of traditional Chinese medicine, including the creation of knowledge graphs for classic formulas and experiences from renowned practitioners [9][20]. - It also supports the clinical trials of new traditional Chinese medicine drugs and aims to shorten the research and development cycle while reducing costs [9][20]. Group 4: Market and Brand Development - The plan includes initiatives to protect intellectual property rights for traditional brands and improve the production processes of existing traditional Chinese medicine products to enhance their clinical and market value [6][17]. - It encourages collaboration between traditional Chinese medicine enterprises and e-commerce platforms to provide efficient purchasing experiences for patients [6][17].

Core Viewpoint - The article discusses the "Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" issued by the Ministry of Industry and Information Technology and other departments, outlining goals for the development of the traditional Chinese medicine (TCM) industry over the next five years, focusing on supply stability, innovation, and digital transformation [1][3]. Group 1: Development Goals - The plan sets four major goals for the TCM industry by 2030, including the establishment of a collaborative development system, enhanced supply capabilities of key TCM raw materials, significant improvements in digital and green levels, and breakthroughs in key technologies [1][3]. - Specific tasks include improving the quality of TCM production, enhancing the collaborative system across the supply chain, and promoting the continuous emergence of innovative TCM products [3][5]. Group 2: Specific Actions - The plan outlines 15 specific tasks across six action areas, including actions to ensure stable supply of raw materials, promote collaborative innovation, enhance manufacturing capabilities, and revitalize the national medicine industry [5][9]. - For TCM raw materials, the plan emphasizes the construction of high-standard production bases and the establishment of a smart circulation and storage management system to ensure stable supply [7][9]. Group 3: Innovation and Product Development - The plan aims to foster the development of innovative TCM products, including the approval of new TCM drugs and the cultivation of major TCM varieties [3][5]. - It encourages collaboration between TCM enterprises and e-commerce platforms to enhance patient access to TCM products and improve the clinical and market value of TCM [5][9]. Group 4: Quality and Standards - The plan includes actions to enhance the quality standards of TCM, such as the formulation of national standards for TCM decoction pieces and the establishment of a quality traceability system [8][9]. - It also highlights the importance of protecting intellectual property rights for traditional brands and improving production processes for existing TCM products [5][9].

方案以稳定供应、协同创新、智能制造、产品推广、服务体系构建为抓手，统筹推进六个方面共15项任 务，包括加快制修订中药材生产加工关键环节生产技术规范和质量标准；运用人工智能、大数据等新一 代信息技术，构建经典名方、名老中医经验方等特色方剂知识图谱和图神经网络；加快制定实施全国中 药饮片炮制规范、配方颗粒国家标准，持续完善饮片质量标准体系。 此外，主要内容还包括整理特色炮制技术、方剂配伍和用药规范，建立完善质量控制体系；开发优势民 族药新产品，培育民族药名品；全方位推动中成药产品临床价值和市场价值双提升；加强中药工业国际 交流合作，鼓励开展优势中成药产品国际注册等。 方案明确，有关方面要将相关任务纳入制造业重点产业链高质量发展行动等工作体系，进一步完善国有 企业和政府引导基金考核和容错机制，鼓励其投资高标准中药原料生产基地建设、新药研发、医疗机构 中药制剂转化等长周期项目，加强中药制造能力提升和重大共性技术成果应用。 转自：贵州日报 新华社北京2月5日电 记者5日获悉，工业和信息化部等八部门日前联合印发《中药工业高质量发展实施 方案（2026—2030年）》，提出到2030年，中药工业全产业链协同发展体系初步形成 ...

2月5日，工业和信息化部等八部门印发《中药工业高质量发展实施方案（2026—2030年）》（以下简称 《实施方案》）。 《实施方案》提出了未来五年的发展目标：到2030年，中药工业全产业链协同发展体系初步形成，重点 中药原料持续稳定供应能力进一步增强，数智化、绿色化水平明显提升，一批关键技术取得突破，产业 协同创新水平显著提高。 设置四大目标 根据工业和信息化部消费品工业司披露的解读，《实施方案》着力推进产业政策、监管政策、医保政策 和临床使用政策的有效协同；充分发挥地方政府发展中药工业的积极性，鼓励各地因地制宜先行先试； 将原料的持续稳定供应作为产业链供应链稳定的"牛鼻子"；将支持中药工业龙头企业发展壮大、不断提 高行业集中度作为重中之重。 《实施方案》重点围绕发展质量、协同体系、创新产品、数智化绿色化转型升级等方面设置了具体的任 务目标。 四是数智化、绿色化转型升级取得突破，制修订10项中药工业数智技术相关行业标准，推动建设一批数 智化创新载体和公共服务平台，支持企业开展数智化改造提升，发布20个数智化转型升级典型案例，建 设20个智能工厂、培育10个绿色工厂。 围绕主要目标，《实施方案》聚焦原料提质稳供 ...

每经记者｜张蕊 每经编辑｜陈柯名 魏官红 记者|张蕊 编辑|陈柯名 魏官红 杜恒峰 校对|程鹏 工业和信息化部等八部门日前联合印发《中药工业高质量发展实施方案（2026—2030年）》（以下简称《方案》）。 《方案》明确，到2030年，中药工业全产业链协同发展体系初步形成，重点中药原料持续稳定供应能力进一步增强，数智化、绿色化水平明显提升，一批 关键技术取得突破，产业协同创新水平显著提高。培育一批引领带动能力突出的中药工业领航企业，培育60个高标准中药原料生产基地。协同体系更加健 全，中药材种植加工、中药研发生产、流通服务等上下游各环节协同更加紧密，建设5个中药工业守正创新中心。 同时，创新产品持续涌现，推动一批中药创新药获批上市，新培育10个中成药大品种，推动一批医疗机构中药制剂转化为中药创新药。数智化、绿色化转 型升级取得突破，制修订10项中药工业数智技术相关行业标准，推动建设一批数智化创新载体和公共服务平台，支持企业开展数智化改造提升，发布20个 数智化转型升级典型案例，建设20个智能工厂、培育10个绿色工厂。 中药企业需构建以临床价值 事实上，近年来，中药行业在政策支持下迎来快速发展。华福证券研报显示 ...

工业和信息化部等八部门日前联合印发《中药工业高质量发展实施方案（2026—2030年）》（以下简称 《方案》）。 《方案》明确，到2030年，中药工业全产业链协同发展体系初步形成，重点中药原料持续稳定供应能力 进一步增强，数智化、绿色化水平明显提升，一批关键技术取得突破，产业协同创新水平显著提高。培 育一批引领带动能力突出的中药工业领航企业，培育60个高标准中药原料生产基地。协同体系更加健 全，中药材种植加工、中药研发生产、流通服务等上下游各环节协同更加紧密，建设5个中药工业守正 创新中心。 同时，创新产品持续涌现，推动一批中药创新药获批上市，新培育10个中成药大品种，推动一批医疗机 构中药制剂转化为中药创新药。数智化、绿色化转型升级取得突破，制修订10项中药工业数智技术相关 行业标准，推动建设一批数智化创新载体和公共服务平台，支持企业开展数智化改造提升，发布20个数 智化转型升级典型案例，建设20个智能工厂、培育10个绿色工厂。 中药企业需构建以临床价值为核心的全链条能力，方能突破同质化竞争 《方案》提出，到2030年，创新产品持续涌现，推动一批中药创新药获批上市，新培育10个中成药大品 种，推动一批医疗机 ...